Not a good buy right now for an impatient investor: price is breaking down below near-term support with bearish momentum and no catalyst.
The bullish longer-term moving-average stack is a plus, but the current MACD deterioration + sharp daily drop suggest downside risk before a clean entry.
Best stance: hold/avoid new entry until price reclaims the 27.61–30.08 zone (S1/pivot) and momentum stabilizes.
Technical Analysis
Trend/Momentum: MACD histogram (-0.0772) is below zero and expanding negatively → bearish momentum is strengthening.
RSI: RSI(6) at 28.17 is near oversold conditions → bounce is possible, but oversold alone is not a reliable buy trigger.
Moving averages: SMA_5 > SMA_20 > SMA_200 indicates a bullish longer-term structure, but today’s selloff is conflicting with that backdrop.
Key levels: Current price 27.385 is slightly below S1 (27.61), suggesting a minor support break; next support is S2 (26.086). Upside levels to reclaim: pivot 30.078, then R1 32.546.
Pattern-based odds (provided): modest upside probabilities (next day/week/month) but not strong enough to override the current momentum breakdown.
suggests the broader structure hasn’t fully broken.
Neutral/Negative Catalysts
→ weak tape.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 556,975,090.71, down -5.75% YoY → top-line contraction.
Net income: 30,552,407.26, down -74.89% YoY → major earnings deterioration.
EPS: 0.03, down -78.57% YoY → profitability per share sharply weaker.
Gross margin: 41.93%, up +10.40% YoY → margin improved, but it did not prevent steep net income/EPS decline.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data provided, so recent Wall Street upgrades/downgrades cannot be confirmed.
Pros view (from available data): improved gross margin and bullish longer-term MA structure.
Cons view (from available data): sharp YoY earnings/EPS decline and current bearish momentum/support break outweigh the positives for a “buy now” decision.
Wall Street analysts forecast EDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast EDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 26.330
Low
0
Averages
0
High
0
0
Current: 26.330
Low
0
Averages
0
High
0
Morgan Stanley
Fernando Amaral
Overweight -> Equal Weight
downgrade
$52 -> $36
AI Analysis
2025-08-19
Reason
Morgan Stanley
Fernando Amaral
Price Target
$52 -> $36
AI Analysis
2025-08-19
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Fernando Amaral downgraded Edenor to Equal Weight from Overweight with a price target of $36, down from $52. The firm cites the stock's uncompelling valuation, lingering regulatory headwinds, and distant company-specific catalysts amid "worse-than-expected regulation", the analyst tells investors in a research note. Argentina macroeconomic changes remain fluid, but the firm prefers to wait for "higher visibility" from the sidelines, Morgan Stanley added.
